Denosumab

Modify Date: 2025-08-31 15:24:24

Denosumab structure	Common Name	Denosumab
	CAS Number	615258-40-7	Molecular Weight	N/A
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₆₄₀₄H₉₉₁₂N₁₇₂₄O₂₀₀₄S₅₀	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Denosumab

Denosumab is a human monoclonal antibody binding to, and inhibiting, the receptor activator of RANKL (TNFSF11). Denosumab can reduce the risk of vertebral, nonvertebral and hip fractures[1], also has anti-cancer activity[2].

Name	Denosumab (usan)

Description	Denosumab is a human monoclonal antibody binding to, and inhibiting, the receptor activator of RANKL (TNFSF11). Denosumab can reduce the risk of vertebral, nonvertebral and hip fractures[1], also has anti-cancer activity[2].
Related Catalog	Research Areas >> Cancer
References	[1]. Moen MD, et al. Denosumab: a review of its use in the treatment of postmenopausal osteoporosis. Drugs Aging. 2011;28(1):63-82. [2]. Chawla S, et al. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. Lancet Oncol. 2019;20(12):1719-1729.

Description

Related Catalog

Research Areas >> Cancer

References

[1]. Moen MD, et al. Denosumab: a review of its use in the treatment of postmenopausal osteoporosis. Drugs Aging. 2011;28(1):63-82.

[2]. Chawla S, et al. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. Lancet Oncol. 2019;20(12):1719-1729.